JP2016539119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539119A5 JP2016539119A5 JP2016533172A JP2016533172A JP2016539119A5 JP 2016539119 A5 JP2016539119 A5 JP 2016539119A5 JP 2016533172 A JP2016533172 A JP 2016533172A JP 2016533172 A JP2016533172 A JP 2016533172A JP 2016539119 A5 JP2016539119 A5 JP 2016539119A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- probiotic composition
- composition
- treatment
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 239000006041 probiotic Substances 0.000 claims 15
- 230000000529 probiotic effect Effects 0.000 claims 15
- 235000018291 probiotics Nutrition 0.000 claims 15
- 241000194029 Enterococcus hirae Species 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 241000605894 Porphyromonas Species 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- 241000862469 Holdemania Species 0.000 claims 3
- 241001468157 Lactobacillus johnsonii Species 0.000 claims 3
- 229940041181 antineoplastic drug Drugs 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 241000194032 Enterococcus faecalis Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 241000736262 Microbiota Species 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229940032049 enterococcus faecalis Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907076P | 2013-11-21 | 2013-11-21 | |
| EP13306597.9 | 2013-11-21 | ||
| EP13306597.9A EP2876167A1 (en) | 2013-11-21 | 2013-11-21 | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment |
| US61/907,076 | 2013-11-21 | ||
| PCT/IB2014/066249 WO2015075688A1 (en) | 2013-11-21 | 2014-11-21 | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019221925A Division JP2020050664A (ja) | 2013-11-21 | 2019-12-09 | 化学療法に対する応答性のマーカーとしての微生物叢組成物、及び癌処置の有効性を改善するための微生物モジュレーター（プレ、プロ又はシンバイオティクス）の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539119A JP2016539119A (ja) | 2016-12-15 |
| JP2016539119A5 true JP2016539119A5 (enExample) | 2017-12-28 |
| JP6662775B2 JP6662775B2 (ja) | 2020-03-11 |
Family
ID=49680948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533172A Active JP6662775B2 (ja) | 2013-11-21 | 2014-11-21 | 化学療法に対する応答性のマーカーとしての微生物叢組成物、及び癌処置の有効性を改善するための微生物モジュレーター（プレ、プロ又はシンバイオティクス）の使用 |
| JP2019221925A Pending JP2020050664A (ja) | 2013-11-21 | 2019-12-09 | 化学療法に対する応答性のマーカーとしての微生物叢組成物、及び癌処置の有効性を改善するための微生物モジュレーター（プレ、プロ又はシンバイオティクス）の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019221925A Pending JP2020050664A (ja) | 2013-11-21 | 2019-12-09 | 化学療法に対する応答性のマーカーとしての微生物叢組成物、及び癌処置の有効性を改善するための微生物モジュレーター（プレ、プロ又はシンバイオティクス）の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10646521B2 (enExample) |
| EP (2) | EP2876167A1 (enExample) |
| JP (2) | JP6662775B2 (enExample) |
| KR (1) | KR102464342B1 (enExample) |
| CN (1) | CN106170557B (enExample) |
| AU (1) | AU2014351348B2 (enExample) |
| CA (1) | CA2931363C (enExample) |
| DK (1) | DK3071709T3 (enExample) |
| ES (1) | ES2764282T3 (enExample) |
| IL (2) | IL245751B (enExample) |
| PT (1) | PT3071709T (enExample) |
| SG (1) | SG10201803877YA (enExample) |
| WO (1) | WO2015075688A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE112016002056T5 (de) | 2015-05-06 | 2018-02-08 | Snipr Technologies Limited | Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen |
| KR102661603B1 (ko) * | 2015-06-01 | 2024-04-29 | 더 유니버서티 오브 시카고 | 공생 미생물총의 조작에 의한 암의 치료 |
| EP3130680A1 (en) * | 2015-08-11 | 2017-02-15 | Universitat de Girona | Method for the detection, follow up and/or classification of intestinal diseases |
| EP4592391A3 (en) | 2015-10-21 | 2025-10-08 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| MA45287A (fr) * | 2015-11-20 | 2018-08-22 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201609811D0 (en) * | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| CN106011281B (zh) * | 2016-07-19 | 2019-04-23 | 浙江大学 | 肠道分节丝状菌鞭毛蛋白的检测方法 |
| CN109715059A (zh) * | 2016-09-16 | 2019-05-03 | 优比欧迈公司 | 用于组表征的方法和系统 |
| EP3518946A4 (en) | 2016-09-27 | 2020-09-09 | Board of Regents, The University of Texas System | METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME |
| KR102644935B1 (ko) * | 2016-12-22 | 2024-03-07 | 인스티튜트 구스타브 루시 | 항-PD1/PD-L1/PD-L2 항체에 대한 반응성의 마커로서의 미생물총 조성물, 및 항-PD1/PD-L1/PD-L2 Ab-기반 치료의 효능을 개선하기 위한 미생물 조정제의 용도 |
| WO2018145082A1 (en) * | 2017-02-06 | 2018-08-09 | New York University | Methods and compositions for treating and diagnosing pancreatic cancers |
| EP3378949A1 (en) * | 2017-03-22 | 2018-09-26 | Assistance Publique - Hôpitaux de Paris | Method for determining the potential efficacy of anticancer treatment |
| MA51770A (fr) | 2017-07-05 | 2020-05-13 | Evelo Biosciences Inc | Compositions et méthodes de traitement du cancer à l'aide de bifidobacterium animalis ssp. lactis |
| MA49982A (fr) * | 2017-08-10 | 2020-06-17 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| EP3476396A1 (en) * | 2017-10-31 | 2019-05-01 | Institut Gustave Roussy | Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same |
| CN107904298A (zh) * | 2017-12-29 | 2018-04-13 | 苏州普瑞森基因科技有限公司 | 一种用于分析肠道微生物的试剂盒及其应用 |
| EP3505177A1 (en) * | 2017-12-29 | 2019-07-03 | Institut Gustave Roussy | Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancer |
| CN111886333A (zh) * | 2018-02-09 | 2020-11-03 | 学校法人庆应义塾 | 诱导cd8+t细胞的组合物和方法 |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| EP3597202A1 (en) * | 2018-07-20 | 2020-01-22 | Maat Pharma | Fecal microbiota composition, for use in reducing treatment-induced inflammation |
| KR20210040997A (ko) * | 2018-08-05 | 2021-04-14 | 다 볼떼라 | 항암제 효능의 개선 방법 |
| US11331269B2 (en) * | 2018-09-06 | 2022-05-17 | Massachusetts Institute Of Technology | Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment |
| EP3629023A1 (en) * | 2018-09-28 | 2020-04-01 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer |
| IL311084A (en) * | 2018-11-30 | 2024-04-01 | Caris Mpi Inc | New generation molecular characterization |
| CN113166815B (zh) * | 2019-02-22 | 2024-06-11 | 深圳华大生命科学研究院 | 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途 |
| EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
| CN113906130A (zh) * | 2019-03-28 | 2022-01-07 | 千实验室株式会社 | 粪杆菌属微生物及包含其的抗癌组合物 |
| CN111991427A (zh) * | 2019-05-07 | 2020-11-27 | 瑞微（深圳）生物科技有限公司 | 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用 |
| EP3965750A4 (en) * | 2019-05-08 | 2023-07-12 | Garvan Institute of Medical Research | Cancer stratification and treatment based on inhibition of nod-2 |
| KR20220116438A (ko) * | 2019-11-01 | 2022-08-23 | 유티아이 리미티드 파트너쉽 | 암 치료를 위한 미생물총 및 대사산물의 힘 활용 |
| WO2021102510A1 (en) * | 2019-11-26 | 2021-06-03 | South Australian Health And Medical Research Institute Limited | Methods and products for reducing side effects associated with use of immune agonist antibodies |
| WO2021112918A1 (en) * | 2019-12-02 | 2021-06-10 | Caris Mpi, Inc. | Pan-cancer platinum response predictor |
| CN114832088A (zh) * | 2022-05-19 | 2022-08-02 | 李臻 | 拉瑞唑来多肽在制备缓解阿霉素心脏毒性药物中的用途 |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| CN116287355A (zh) * | 2023-05-12 | 2023-06-23 | 中国医学科学院北京协和医院 | 上消化道肿瘤化疗疗效及不良反应的肠道菌群预测模型 |
| CN117237952B (zh) * | 2023-11-15 | 2024-02-09 | 山东大学 | 基于免疫地形图的染色病理切片细胞分布标注方法及系统 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08295631A (ja) | 1995-02-27 | 1996-11-12 | Nichinichi Seiyaku Kk | 制癌増強剤 |
| JPH1029946A (ja) * | 1996-07-15 | 1998-02-03 | Nichinichi Seiyaku Kk | 液性免疫回復剤 |
| TW200904340A (en) | 2007-05-11 | 2009-02-01 | Mannatech Inc | Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same |
| CA2736774C (en) | 2008-09-19 | 2017-08-22 | Institut Curie | Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor |
| AU2009293475A1 (en) * | 2008-09-19 | 2010-03-25 | Nestec S.A. | Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
| JP5717116B2 (ja) * | 2008-12-22 | 2015-05-13 | 学校法人昭和大学 | 抗原特異的ヒトＴｈ１７細胞を調整する方法 |
| US8828944B2 (en) * | 2010-04-22 | 2014-09-09 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
-
2013
- 2013-11-21 EP EP13306597.9A patent/EP2876167A1/en not_active Withdrawn
-
2014
- 2014-11-21 ES ES14812648T patent/ES2764282T3/es active Active
- 2014-11-21 DK DK14812648.5T patent/DK3071709T3/da active
- 2014-11-21 KR KR1020167016068A patent/KR102464342B1/ko active Active
- 2014-11-21 PT PT148126485T patent/PT3071709T/pt unknown
- 2014-11-21 SG SG10201803877YA patent/SG10201803877YA/en unknown
- 2014-11-21 JP JP2016533172A patent/JP6662775B2/ja active Active
- 2014-11-21 US US15/038,073 patent/US10646521B2/en active Active
- 2014-11-21 AU AU2014351348A patent/AU2014351348B2/en active Active
- 2014-11-21 WO PCT/IB2014/066249 patent/WO2015075688A1/en not_active Ceased
- 2014-11-21 CN CN201480063481.9A patent/CN106170557B/zh active Active
- 2014-11-21 CA CA2931363A patent/CA2931363C/en active Active
- 2014-11-21 EP EP14812648.5A patent/EP3071709B1/en active Active
-
2016
- 2016-05-19 IL IL245751A patent/IL245751B/en active IP Right Grant
-
2019
- 2019-08-05 IL IL268526A patent/IL268526B/en unknown
- 2019-12-09 JP JP2019221925A patent/JP2020050664A/ja active Pending
-
2020
- 2020-04-21 US US16/854,117 patent/US11344586B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539119A5 (enExample) | ||
| FI3468573T3 (fi) | Clostridium difficile -infektion hoito | |
| JP2019001815A5 (enExample) | ||
| NZ745678A (en) | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity | |
| JP2018199695A5 (enExample) | ||
| WO2018013583A3 (en) | Medicinal vaginal lactobacillus cocktail | |
| JP2014158488A5 (enExample) | ||
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| HRP20191344T1 (hr) | Sastavi koji sadrže bakterijske sojeve | |
| WO2016081518A3 (en) | Engineered gamma delta t-cells | |
| HK1252759A1 (zh) | 肽寡核苷酸缀合物 | |
| MY151137A (en) | Probiotics to improve gut microbiota | |
| EP4417261A3 (en) | Bacteriotherapy | |
| JP2016501013A5 (enExample) | ||
| HK1205939A1 (en) | Parenteral formulations for administering macrolide antibiotics | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2018522028A5 (enExample) | ||
| JP2020513780A5 (enExample) | ||
| EA201390417A1 (ru) | Антидиабетические твердые фармацевтические композиции | |
| RU2019115476A (ru) | Композиция для профилактического или терапевтического лечения заболеваний печени | |
| WO2011006084A3 (en) | Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof | |
| ATE536102T1 (de) | Probiotischer stamm von lactobacillus delbrueckii subsp bulgaricus | |
| RU2008129232A (ru) | Способ лечения туберкулеза легких у больных вич-инфекцией | |
| Srikanth et al. | Enhanced regression of tumors in mice with combined chemotherapy and immunotherapy | |
| Na et al. | Protective effect of Ginsan against Vibrio vulnificus infection |